Cargando…
Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
PURPOSE: We previously investigated the efficacy and safety of adding 0.1% brimonidine (Brim) or 0.5% timolol (Tim) to prostaglandin analogue (PGA) monotherapy to treat patients with normal-tension glaucoma (NTG) with intraocular pressure (IOP) of ≤16 mmHg. Herein, we describe an additional post-hoc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274234/ https://www.ncbi.nlm.nih.gov/pubmed/34262247 http://dx.doi.org/10.2147/OPTH.S318392 |
_version_ | 1783721522382241792 |
---|---|
author | Yoshikawa, Keiji Mizoue, Shiro Nitta, Koji Onishi, Hiroshi Ikeda, Masaharu Mizuno, Akemi Kawazoe, Kaori Tamada, Yoshiyuki Takeda, Ryuji Matsumoto, Shun |
author_facet | Yoshikawa, Keiji Mizoue, Shiro Nitta, Koji Onishi, Hiroshi Ikeda, Masaharu Mizuno, Akemi Kawazoe, Kaori Tamada, Yoshiyuki Takeda, Ryuji Matsumoto, Shun |
author_sort | Yoshikawa, Keiji |
collection | PubMed |
description | PURPOSE: We previously investigated the efficacy and safety of adding 0.1% brimonidine (Brim) or 0.5% timolol (Tim) to prostaglandin analogue (PGA) monotherapy to treat patients with normal-tension glaucoma (NTG) with intraocular pressure (IOP) of ≤16 mmHg. Herein, we describe an additional post-hoc stratifying analysis of the possible differences in the effect of IOP-lowering and pulse rate (PR) after adjunctive Brim or Tim to PGA. PATIENTS AND METHODS: This study included 128 subjects. Patients with NTG treated with PGA were stratified based on their baseline IOP. The changes in IOP from baseline and the effect of patient factors on IOP changes were investigated. Patients were stratified by age for investigation of their PR and blood pressure (BP). The change and the effect of patient factors on PR and BP were investigated. RESULTS: After stratification analysis, in 52 eyes treated with Brim and 61 eyes with Tim with baseline IOP 12 ≤ IOP ≤ 16 mmHg, both eye drops lowered IOP significantly (P < 0.0001), and the IOP-lowering efficacy of Brim was non-inferior to that of Tim. However, in 9 Brim- and 6 Tim-treated eyes with baseline IOP of <12 mmHg, no statistically significant decrease in IOP was evident with either eye drop. In the Tim group, PR decreased significantly (P < 0.05) after stratification by age. CONCLUSION: The IOP-lowering efficacy of Brim was non-inferior to that of Tim after stratification by baseline IOP (12 ≤ IOP ≤ 16 mmHg). The discrepancy in the IOP-lowering effects of Brim and Tim observed in the previous study was thought to be related to enrolled subjects with low baseline IOP. PR decreased significantly in the Tim group even after age stratification. PR should be considered when selecting β-blockers for glaucoma treatment. |
format | Online Article Text |
id | pubmed-8274234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82742342021-07-13 Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma Yoshikawa, Keiji Mizoue, Shiro Nitta, Koji Onishi, Hiroshi Ikeda, Masaharu Mizuno, Akemi Kawazoe, Kaori Tamada, Yoshiyuki Takeda, Ryuji Matsumoto, Shun Clin Ophthalmol Original Research PURPOSE: We previously investigated the efficacy and safety of adding 0.1% brimonidine (Brim) or 0.5% timolol (Tim) to prostaglandin analogue (PGA) monotherapy to treat patients with normal-tension glaucoma (NTG) with intraocular pressure (IOP) of ≤16 mmHg. Herein, we describe an additional post-hoc stratifying analysis of the possible differences in the effect of IOP-lowering and pulse rate (PR) after adjunctive Brim or Tim to PGA. PATIENTS AND METHODS: This study included 128 subjects. Patients with NTG treated with PGA were stratified based on their baseline IOP. The changes in IOP from baseline and the effect of patient factors on IOP changes were investigated. Patients were stratified by age for investigation of their PR and blood pressure (BP). The change and the effect of patient factors on PR and BP were investigated. RESULTS: After stratification analysis, in 52 eyes treated with Brim and 61 eyes with Tim with baseline IOP 12 ≤ IOP ≤ 16 mmHg, both eye drops lowered IOP significantly (P < 0.0001), and the IOP-lowering efficacy of Brim was non-inferior to that of Tim. However, in 9 Brim- and 6 Tim-treated eyes with baseline IOP of <12 mmHg, no statistically significant decrease in IOP was evident with either eye drop. In the Tim group, PR decreased significantly (P < 0.05) after stratification by age. CONCLUSION: The IOP-lowering efficacy of Brim was non-inferior to that of Tim after stratification by baseline IOP (12 ≤ IOP ≤ 16 mmHg). The discrepancy in the IOP-lowering effects of Brim and Tim observed in the previous study was thought to be related to enrolled subjects with low baseline IOP. PR decreased significantly in the Tim group even after age stratification. PR should be considered when selecting β-blockers for glaucoma treatment. Dove 2021-07-06 /pmc/articles/PMC8274234/ /pubmed/34262247 http://dx.doi.org/10.2147/OPTH.S318392 Text en © 2021 Yoshikawa et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Yoshikawa, Keiji Mizoue, Shiro Nitta, Koji Onishi, Hiroshi Ikeda, Masaharu Mizuno, Akemi Kawazoe, Kaori Tamada, Yoshiyuki Takeda, Ryuji Matsumoto, Shun Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma |
title | Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma |
title_full | Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma |
title_fullStr | Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma |
title_full_unstemmed | Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma |
title_short | Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma |
title_sort | stratification-based investigation of adjunctive brimonidine or timolol to a prostaglandin analogue in japanese patients with normal-tension glaucoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274234/ https://www.ncbi.nlm.nih.gov/pubmed/34262247 http://dx.doi.org/10.2147/OPTH.S318392 |
work_keys_str_mv | AT yoshikawakeiji stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma AT mizoueshiro stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma AT nittakoji stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma AT onishihiroshi stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma AT ikedamasaharu stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma AT mizunoakemi stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma AT kawazoekaori stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma AT tamadayoshiyuki stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma AT takedaryuji stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma AT matsumotoshun stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma |